Audentes Therapeutics (BOLD) Stock Price, News & Analysis

Company Overview

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $2.36 to $2.58
• 50-Day Range: $59.97 to $59.97
• 52-Week Range: $1.06 to $12.65
• Volume: 96,520 shs
• Average Volume: 89,568 shs
• Market Capitalization: $27.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Moderate Buy

Audentes Therapeutics Stock Analysis - MarketRank™

Audentes Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 830th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Audentes Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Audentes Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Audentes Therapeutics are expected to grow in the coming year, from ($3.85) to ($3.35) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.85% of the float of Audentes Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Audentes Therapeutics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Audentes Therapeutics has recently increased by 4.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Audentes Therapeutics does not currently pay a dividend.

Dividend Growth

Audentes Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.85% of the float of Audentes Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Audentes Therapeutics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Audentes Therapeutics has recently increased by 4.65%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Audentes Therapeutics this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for BOLD on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Audentes Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.30% of the stock of Audentes Therapeutics is held by insiders.

BOLD Stock Analysis - Frequently Asked Questions

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings results on Thursday, March, 27th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.74).

When did Audentes Therapeutics IPO?

Audentes Therapeutics (BOLD) raised $100 million in an initial public offering on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share.

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 4/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BOLD
• CIK: 1628738
• Web: www.audentestx.com
• Phone: 415-818-1001
• Fax: N/A
• Employees: 207
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +1,865.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,430,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -321.10%
• Return on Assets: -40.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.03
• Quick Ratio: 17.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 22,300,000
• Free Float: 21,118,000
• Market Cap: $26.09 million
• Optionable: No Data
• Beta: N/A